MedTrace Logo

Octagam 5% Versus Comparator Post Marketing Trial

NCT01859754 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 623

Last updated 2019-06-10

No results posted yet for this study

Summary

Study Design:

This is a 2 arm non-interventional trial that will compare the occurrence of adverse drug reactions between Octagam 5% and other marketed IVIG infusion treatments.

Conditions

  • Primary Immune Deficiency Disorder

Interventions

BIOLOGICAL

Octagam 5%

Intravenous immunoglobulin 5%

BIOLOGICAL

Other marketed IVIG product

Any intravenous immunoglobulin marketed product approved for the treatment of PID

Sponsors & Collaborators

  • Octapharma

    lead INDUSTRY

Principal Investigators

  • Wolfgang Frenzel · International Medical Monitor, Octapharma AG

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-21
Primary Completion
2019-05-22
Completion
2019-05-22

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01859754 on ClinicalTrials.gov